January 12, 2022

Monoclonal status RED

LMH Health remains in Tier 3/RED for IV monoclonal antibody (mAB) therapy, as our allocation was only six doses this week. Please note that it is very likely we will exhaust our supply before an allocation can arrive next week. Once this happens, we will announce that we are in Tier 4/BLUE, meaning that no monoclonal antibodies are available. Given the greater than 80% dominance of the Omicron variant, we cannot use the previous two agents (Bamlanivimab/Etesevimab or Casirivimab/Imdevimab).

It is important to remember the following:

• If the patient does not have four high-risk criteria, they will not be contacted for an appointment. 
  Please note: Multiple comorbidities within the same category will not count as additional high-risk criteria (i.e. a patient with CAD and HTN will solely fulfill the cardiovascular disease category and not be counted as two separate high-risk qualifiers).
• Please do not have patients call the Treatment and Procedure Center (TPC).
• Make sure your orders are completely filled out before faxing them to TPC.
• Prepare your patients for the strong possibility there could not be mAB available, despite meeting the current criteria.

Please visit lmh.org/mab for additional information.